|
|
Article: Raptor Closes Reverse Merger, Raises $5M For RAP Platform.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Gaining a public listing through a reverse merger, start-up Raptor Pharmaceutical Inc. completed a $5 million financing to support research and development of drug candidates based on its receptor-associated protein (RAP) technology.
Established last year, Raptor is a "literal start-up," said co-founder and CEO Christopher Starr, adding that the company's lab is being built "even as we speak" in Novato, Calif., not far from BioMarin Pharmaceutical Inc., the last company co-founded by Starr.
In fact, Raptor's intellectual property was acquired from BioMarin earlier this year. It's a technology "that [co-founder] Todd [Zankel] and I ...